| Metric | Value (₹ Cr) | Q3 FY26 | Q4 FY25 |
|---|---|---|---|
| Revenue | 2.8K | 28.6% | 0.1% |
| Total Income | 2.8K | 28.2% | 0.1% |
| Expenditure | 2.6K | 15.4% | 2.1% |
| PBT | 29.43 | 128.3% | 88.5% |
| Net Profit | -8.82 | 93.5% | 105.8% |
| OPM | 10.35% | 3.12pp | 10.02pp |
| NPM | -0.32% | 5.92pp | 5.81pp |
| EPS | 0.07 | 93.2% | 94.0% |
Piramal Pharma Q4FY26 Revenue ₹2,752 Cr, FY26 ₹8,869 Cr
28 Apr 2026 · 28 Apr, 9:32 pm
Summary
Piramal Pharma Limited announced its Q4 and full-year FY26 results, reporting consolidated revenue from operations of ₹8,869 crore for FY26, a 3% year-over-year decline, while Q4FY26 revenue remained flat at ₹2,752 crore. The company's EBITDA for FY26 decreased significantly by 28% to ₹1,135 crore, resulting in a 13% EBITDA Margin. A substantial impairment loss of ₹196 crore (₹176 crore in Q4FY26) led to a net loss of ₹(326) crore for the full year. Chairperson Nandini Piramal noted FY26 as a transitional year, but expressed optimism for FY27 with expected growth across all three businesses, accompanied by accelerated growth in EBITDA and PAT, driven by recovery in biopharma funding, the Kenalog® acquisition, and consumer healthcare momentum.
Key Highlights
- 1
Piramal Pharma Limited reported consolidated revenue from operations of ₹8,869 crore for FY26, marking a 3% decline year-over-year.
- 2
For Q4FY26, revenue from operations stood at ₹2,752 crore, showing a flat performance compared to the previous year.
- 3
Consolidated EBITDA for FY26 decreased by 28% to ₹1,135 crore, resulting in an EBITDA Margin of 13%.
- 4
The company recorded a significant net loss after exceptional items of ₹(326) crore for FY26, a substantial shift from a ₹91 crore profit in FY25, primarily due to an impairment loss.
- 5
An exceptional impairment loss of ₹176 crore was recognized in Q4FY26 related to intangible assets under development, contributing to a Q4 net loss of ₹(9) crore.
- 6
Despite the financial headwinds, the company's Net Debt remained stable with no increase over FY25.
- 7
Piramal Pharma invested US$94Mn in Capex during FY26, with key expansions at Lexington and Riverview sites progressing as planned.
Management Comments
Nandini Piramal
FY26 was a transitional year, shaped by external disruptions and certain business-specific factors. Despite these challenges, we exited the year on a stronger note, with clear momentum across all our businesses. The meaningful recovery in biopharma funding seen from Sep’25, is translating into good RFP momentum and healthy pick up in order inflows in our CDMO business. In the CHG business, the recently completed Kenalog® acquisition alongside ramp up of inhalation anesthesia sales in ex-US markets are expected to be key growth drivers. Our Consumer Healthcare business is also well positioned to sustain its growth momentum with margin improvement driven by Power Brands and rapid growth in e‑commerce. Overall, all three businesses are well positioned to deliver growth in FY27, accompanied by accelerated growth in EBITDA and PAT.
Informational and educational content only. Not investment advice.